BACKGROUND: We assessed the efficacy and safety of programmed cell death 1 (PD-1) inhibition with pembrolizumab in patients with advanced non-small-cell lung cancer enrolled in a phase 1 study. We also sought to define and validate an expression level of the PD-1 ligand 1 (PD-L1) that is associated with the likelihood of clinical benefit. METHODS: We assigned 495 patients receiving pembrolizumab (at a dose of either 2 mg or 10 mg per kilogram of body weight every 3 weeks or 10 mg per kilogram every 2 weeks) to either a training group (182 patients) or a validation group (313 patients). We assessed PD-L1 expression in tumor samples using immunohistochemical analysis, with results reported as the percentage of neoplastic cells with staining for membranous PD-L1 (proportion score). Response was assessed every 9 weeks by central review. RESULTS: Common side effects that were attributed to pembrolizumab were fatigue, pruritus, and decreased appetite, with no clear difference according to dose or schedule. Among all the patients, the objective response rate was 19.4%, and the median duration of response was 12.5 months. The median duration of progression-free survival was 3.7 months, and the median duration of overall survival was 12.0 months. PD-L1 expression in at least 50% of tumor cells was selected as the cutoff from the training group. Among patients with a proportion score of at least 50% in the validation group, the response rate was 45.2%. Among all the patients with a proportion score of at least 50%, median progression-free survival was 6.3 months; median overall survival was not reached. CONCLUSIONS: Pembrolizumab had an acceptable side-effect profile and showed antitumor activity in patients with advanced non-small-cell lung cancer. PD-L1 expression in at least 50% of tumor cells correlated with improved efficacy of pembrolizumab. (Funded by Merck; KEYNOTE-001 ClinicalTrials.gov number, NCT01295827.).
Pembrolizumab for the treatment of non-small-cell lung cancer / Garon, Eb; Rizvi, Na; Hui, R; Leighl, N; Balmanoukian, As; Eder, Jp; Patnaik, A; Aggarwal, C; Gubens, M; Horn, L; Carcereny, E; Ahn, Mj; Felip, E; Lee, Js; Hellmann, Md; Hamid, O; Goldman, Jw; Soria, Jc; Dolled-Filhart, M; Rutledge, Rz; Zhang, J; Lunceford, Jk; Rangwala, R; Lubiniecki, Gm; Roach, C; Emancipator, K; Gandhi, L; Hui, R; Chu, Q; Leighl, N; Chomy, F; Dansin, E; Lena, H; Quere, G; Soria, Jc; Cappuzzo, F; Garassino, M; Melotti, B; Morabito, A; Santini, D; Brunsvig, P; Fløtten, Ø; Ahn, Mj; Lee, Dh; Lee, Js; Carcereny, E; Felip, E; Insa, A; Yang, Jc; Tsai, Cm; Arkenau, Ht; Grummet, S; Middleton, G; Aggarwal, C; Balmanoukian, As; Bessudo, A; Blumenschein GR, Jr; Dronca, R; Eder, Jp; Garon, Eb; Gandhi, L; Goldman, J; Gubens, M; Hager, S; Hamid, O; Hellmann, Md; Horn, L; Johnson, E; O'Day, S; Patnaik, A; Ramalingam, S; Rizvi, Na; Ross, H; Socinski, M.. - In: THE NEW ENGLAND JOURNAL OF MEDICINE. - ISSN 0028-4793. - 372(21):(2015), pp. 2018-2028. [10.1056/NEJMoa1501824]
Pembrolizumab for the treatment of non-small-cell lung cancer
Santini D;
2015
Abstract
BACKGROUND: We assessed the efficacy and safety of programmed cell death 1 (PD-1) inhibition with pembrolizumab in patients with advanced non-small-cell lung cancer enrolled in a phase 1 study. We also sought to define and validate an expression level of the PD-1 ligand 1 (PD-L1) that is associated with the likelihood of clinical benefit. METHODS: We assigned 495 patients receiving pembrolizumab (at a dose of either 2 mg or 10 mg per kilogram of body weight every 3 weeks or 10 mg per kilogram every 2 weeks) to either a training group (182 patients) or a validation group (313 patients). We assessed PD-L1 expression in tumor samples using immunohistochemical analysis, with results reported as the percentage of neoplastic cells with staining for membranous PD-L1 (proportion score). Response was assessed every 9 weeks by central review. RESULTS: Common side effects that were attributed to pembrolizumab were fatigue, pruritus, and decreased appetite, with no clear difference according to dose or schedule. Among all the patients, the objective response rate was 19.4%, and the median duration of response was 12.5 months. The median duration of progression-free survival was 3.7 months, and the median duration of overall survival was 12.0 months. PD-L1 expression in at least 50% of tumor cells was selected as the cutoff from the training group. Among patients with a proportion score of at least 50% in the validation group, the response rate was 45.2%. Among all the patients with a proportion score of at least 50%, median progression-free survival was 6.3 months; median overall survival was not reached. CONCLUSIONS: Pembrolizumab had an acceptable side-effect profile and showed antitumor activity in patients with advanced non-small-cell lung cancer. PD-L1 expression in at least 50% of tumor cells correlated with improved efficacy of pembrolizumab. (Funded by Merck; KEYNOTE-001 ClinicalTrials.gov number, NCT01295827.).I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
